Related Experiment Video
Updated: Feb 28, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review
Adrian G Sacher1, Kimberly M Komatsubara1, Geoffrey R Oxnard2
1Columbia University/New York-Presbyterian Hospital, New York, New York.
Abstract:
The rational treatment of metastatic NSCLC hinges on the timely detection of potentially targetable genomic alterations to guide therapy. Recent advances in highly sensitive genotyping technologies have allowed for development of novel plasma genotyping assays that are capable of noninvasively detecting targetable alterations in plasma cell-free DNA without reliance on traditional tissue genotyping. The rapid development of plasma genotyping has led to an explosion in the number of assay platforms available from both commercial and laboratory sources. The sheer number of such platforms has led to confusion among oncologists as to both the test characteristics and limitations of individual plasma genotyping assays and the clinical context in which these tests may be utilized either alone or in combination with traditional tissue genotyping. Reliable data from prospective validation against a tissue genotyping reference standard are available for only a limited number of platforms. Careful retrospective validation of alternative platforms utilizing paired tissue and plasma specimens collected under the auspices of clinical trials represent an alternative but reliable validation strategy. A consistent trend among these well-validated plasma genotyping assays has been the observation of high specificity and positive predictive value and more limited sensitivity. At present, validated assays can be considered actionable in instances in which a targetable genomic alteration is detected or an alternative nontargetable driver mutation is detected and can be used to infer the absence of one of the former.
Insights
Plasma genotyping assays offer a noninvasive method for detecting genomic alterations in metastatic non-small cell lung cancer (NSCLC). While these tests show high specificity, their limited sensitivity requires careful interpretation alongside traditional tissue genotyping.
Area of Science:
- Molecular Oncology
- Genomic Medicine
- Diagnostic Technologies
Background:
- Effective treatment of metastatic non-small cell lung cancer (NSCLC) relies on identifying targetable genomic alterations.
- Traditional tissue genotyping is invasive and may not always be feasible.
- Advances in genotyping technology have led to the development of plasma-based (liquid biopsy) assays for noninvasive detection of cell-free DNA alterations.
Purpose of the Study:
- To address the confusion among oncologists regarding the characteristics, limitations, and clinical utility of numerous available plasma genotyping platforms.
- To evaluate the reliability and validation strategies for plasma genotyping assays in comparison to tissue genotyping.
- To clarify the role of plasma genotyping in guiding NSCLC therapy.
Main Methods:
- Review of available literature and data on plasma genotyping assays for NSCLC.
- Analysis of validation strategies, including prospective studies against tissue genotyping and retrospective validation using paired tissue-plasma specimens from clinical trials.
- Assessment of assay performance characteristics, focusing on specificity, positive predictive value, and sensitivity.
Main Results:
- A wide array of plasma genotyping platforms are commercially available, leading to challenges in understanding their individual performance.
- Prospective validation data against tissue genotyping are limited for many platforms.
- Well-validated plasma genotyping assays consistently demonstrate high specificity and positive predictive value, but often have limited sensitivity.
Conclusions:
- Validated plasma genotyping assays are actionable when detecting targetable genomic alterations or non-targetable driver mutations.
- The ability to infer the absence of certain alterations based on plasma genotyping results is valuable.
- Careful consideration of assay validation and performance characteristics is crucial for appropriate clinical utilization, potentially in conjunction with tissue genotyping.
